Skip to main content
Year archive

STARPHARMA HOLDINGS LIMITED — 2020 filings

All 75 regulatory filings released by STARPHARMA HOLDINGS LIMITED (SPL) in 2020, sourced directly from the official regulator.

75 Filings
2020 Period
2020 filings (75)
Filing Released Lang
Change in substantial holding 5 pages 87.7KB
Major Shareholding Notification
2020-12-23 English
Change in substantial holding 6 pages 477.5KB
Major Shareholding Notification
2020-12-21 English
VIRALEZE COVID-19 nasal spray study to commence in January 2 pages 68.9KB
Regulatory Filings
2020-12-21 English
VIRALEZE COVID-19 nasal spray to be ready for market Q1CY21 3 pages 116.7KB
Regulatory Filings
2020-12-09 English
Appendix 3G 12 pages 137.1KB
Share Issue/Capital Change
2020-11-23 English
Change in Director's Interest Notice - J Fairley 2 pages 81.6KB
Director's Dealing
2020-11-23 English
AGM Chairman address and CEO presentation 40 pages 3.1MB
AGM Information
2020-11-19 English
2020 AGM Results 2 pages 59.7KB
Declaration of Voting Results & Voting Rights Announcements
2020-11-19 English
Retirement of non-executive director Richard Hazleton 4 pages 191.2KB
Board/Management Information
2020-11-19 English
SPL7013 shows potent antiviral activity in RSV 4 pages 98.6KB
Regulatory Filings
2020-11-18 English
Appendix 3G 12 pages 139.8KB
Share Issue/Capital Change
2020-11-12 English
Appendix 2A 14 pages 176.2KB
Capital/Financing Update
2020-11-03 English
Change in Director's Interest Notice - Peter Turvey 2 pages 81.8KB
Director's Dealing
2020-11-03 English
Change in Director's Interest Notice - J Fairley 2 pages 158.4KB
Director's Dealing
2020-11-03 English
Change in Director's Interest Notice - R Thomas 2 pages 82.1KB
Director's Dealing
2020-11-03 English
Quarterly Cashflow and Activities Report 7 pages 183.7KB
Interim / Quarterly Report
2020-10-29 English
Appendix 2A 14 pages 180.3KB
Regulatory Filings
2020-10-29 English
Completion of Placement and SPP raises $48.9M in total 2 pages 54.7KB
Capital/Financing Update
2020-10-28 English
Starpharma receives $5.7M R&D tax incentive refund 2 pages 54.9KB
Regulatory Filings
2020-10-20 English
Shareholder Update October 2020 4 pages 481.7KB
Capital/Financing Update
2020-10-19 English
Notice of Annual General Meeting/Proxy Form 27 pages 3.3MB
AGM Information
2020-10-18 English
Change in substantial holding 3 pages 192.5KB
Major Shareholding Notification
2020-10-08 English
Change in substantial holding 11 pages 1.7MB
Major Shareholding Notification
2020-10-07 English
Change in substantial holding 7 pages 484.8KB
Major Shareholding Notification
2020-10-07 English
Change in substantial holding 5 pages 161.8KB
Major Shareholding Notification
2020-10-07 English
Share Purchase Plan offer document 16 pages 408.0KB
Capital/Financing Update
2020-10-06 English
Appendix 2A 14 pages 179.9KB
Capital/Financing Update
2020-10-05 English
Cleansing Notice 2 pages 84.0KB
Capital/Financing Update
2020-10-05 English
Change in Director's Interest Notice - J Fairley 2 pages 81.5KB
Director's Dealing
2020-10-04 English
Change in Director's Interest Notice - R Thomas 2 pages 80.8KB
Director's Dealing
2020-10-04 English
Starpharma completes oversubscribed A$45M placement 3 pages 69.1KB
Capital/Financing Update
2020-09-29 English
Investor Presentation 44 pages 3.3MB
Investor Presentation
2020-09-29 English
Proposed issue of Securities - SPL 9 pages 37.6KB
Capital/Financing Update
2020-09-29 English
Trading Halt 2 pages 152.8KB
Capital/Financing Update
2020-09-27 English
VivaGel BV secures TGA approval for prevention of BV 2 pages 64.3KB
Regulatory Filings
2020-09-24 English
2020 Annual General Meeting 2 pages 52.1KB
AGM Information
2020-09-22 English
Appendix 2A 14 pages 175.3KB
Regulatory Filings
2020-09-22 English
Change in substantial holding 5 pages 163.0KB
Major Shareholding Notification
2020-09-17 English
Change in substantial holding 3 pages 198.3KB
Major Shareholding Notification
2020-09-16 English
Starpharma to present at OTCQX Life Sciences Investor Forum 36 pages 2.9MB
Investor Presentation
2020-09-16 English
SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2 3 pages 188.2KB
Regulatory Filings
2020-09-13 English
Starpharma awarded $1M MRFF funding for COVID-19 spray 3 pages 96.9KB
Capital/Financing Update
2020-09-02 English
Change in substantial holding 5 pages 164.6KB
Major Shareholding Notification
2020-09-02 English
Change in substantial holding 3 pages 202.1KB
Major Shareholding Notification
2020-08-31 English
SPL creates slow release soluble DEP remdesivir nanoparticle 3 pages 93.0KB
Regulatory Filings
2020-08-31 English
Starpharma annual report and full year financial results 95 pages 6.1MB
Annual Report
2020-08-26 English
Appendix 4G - Corporate Governance Statement 9 pages 132.2KB
Governance Information
2020-08-26 English
SPL7013 nasal spray for COVID19 development update 5 pages 273.9KB
Capital/Financing Update
2020-08-24 English
Starpharma signs new DEP partnership with Chase Sun 2 pages 59.8KB
Regulatory Filings
2020-08-16 English
DEP docetaxel and gemcitabine combination trial commences 3 pages 68.9KB
Regulatory Filings
2020-07-29 English
Quarterly Cashflow and Activities Report 7 pages 175.9KB
Interim / Quarterly Report
2020-07-29 English
AZD0466 trial opens MD Anderson Cancer Center as a site 2 pages 55.6KB
Regulatory Filings
2020-07-26 English
New Australian site opening for DEP trials 2 pages 57.0KB
Regulatory Filings
2020-07-08 English
DEP irinotecan boosts immuno-oncology in colon cancer models 6 pages 115.6KB
Regulatory Filings
2020-06-28 English
DEP products showcased at AACR 2020 3 pages 71.4KB
Regulatory Filings
2020-06-22 English
Starpharma to present at OTCQX Virtual Investor Conference 1
Investor Presentation
2020-06-17 English
DEP lutetium effective in human prostate cancer model 3 pages 112.2KB
Regulatory Filings
2020-06-16 English
VivaGel BV launched in central and eastern Europe 2 pages 59.0KB
Regulatory Filings
2020-06-15 English
Becoming a substantial holder 4 pages 215.0KB
Major Shareholding Notification
2020-06-14 English
Becoming a substantial holder 12 pages 940.4KB
Regulatory Filings
2020-05-25 English
Shareholder Update May 2020 4 pages 622.5KB
Interim / Quarterly Report
2020-05-13 English
DEP irinotecan phase 2 commences after positive phase 1 4 pages 112.3KB
Regulatory Filings
2020-05-06 English
Starpharma presents at Macquarie Australia Conference 2 pages 52.0KB
Investor Presentation
2020-05-04 English
SPL7013 shows significant activity against coronavirus 3 pages 72.0KB
Regulatory Filings
2020-04-14 English
Quarterly Cashflow and Activity Report 7 pages 512.9KB
Interim / Quarterly Report
2020-04-06 English
Appendix 2A 14 pages 251.2KB
Share Issue/Capital Change
2020-03-19 English
Okamoto licenses VivaGel antiviral condom in Asian countries 2 pages 56.6KB
Regulatory Filings
2020-03-03 English
Starpharma appoints David McIntyre and Appendix 3X 4 pages 223.3KB
Board/Management Information
2020-03-01 English
Interim Report and Half-Year Financial Results 23 pages 569.1KB
Interim / Quarterly Report
2020-02-23 English
VivaGel BV launched in Asia 2 pages 53.3KB
Regulatory Filings
2020-02-12 English
David McIntyre appointed as non-executive director 2 pages 53.9KB
Board/Management Information
2020-02-11 English
Starpharma receives US$3M milestone from AstraZeneca 2 pages 56.5KB
Capital/Financing Update
2020-02-10 English
Shareholder Update January 2020 4 pages 647.7KB
Annual Report
2020-01-29 English
Quarterly Cashflow Report 6 pages 96.7KB
Interim / Quarterly Report
2020-01-28 English
Appendix 3B 8 pages 165.5KB
Share Issue/Capital Change
2020-01-23 English